Elli Lilly Case

In: Business and Management

Submitted By pkokabi
Words 589
Pages 3
Parinaz Kokabi
OP 300

“Elli Lilly and the Company: The Flexible Facility Decision” case analysis

Due to the fierce competition in pharmaceutical industry, Elli Lily has to change its product development process to retain its situation in the market. Steve Mueller, manager of strategic facilities planning, must suggest the company what type of manufacturing facilities to construct. These new facilities were needed for three new products (Alfatine, Betazin, and Clorazin), which the company expected to launch in 1996. His decision will be based on decreasing the lead-time by 50% and reducing the costs by 25%. According to the case, Mueller suggest three options: one option is to build one specialized facility; the second option is to build one flexible facility, and the third options which is stated under the second option is a combination of specialized and flexible facility. The first choice, building a specialized facility, will not reduce the production lead-time. In addition, since the facility is built only for one type of product, if that product cannot be launched to the market the part of the facility might have to be retrofitted to produce another product. Further, it can cause delays in production, which can cost the company millions of dollars in loss. However, this option is very productive (almost 16,000 kilograms of output per rig at 80% of utilization) because the plant is dedicated to a set of special products and there is no changeover. Moreover, building a special facility represent a lower construction cost of $37.50 million and an annually operation cost of $6.80 million (Exhibit 3). The second choice, building a flexible facility, will reduce lead-time only for subsequent new products and not for Alfatine, Betazine, and Clorazine. In addition the construction cost ($150 million) and operation cost per year ($9.48 million) of…...

Similar Documents

Eli Lilly

...purchase of Eli Lilly common stock. We performed various analyses, which included strategy analysis, fundamental analysis, valuation, and risk assessment. Our absolute valuation calculation shows that Eli Lilly is slightly undervalued however; our relative valuation calculation shows that Eli Lilly is fairly valued. We decided to use the relative valuation recommendation because of the risk that is involved in the industry today. Current risk factors that are threatening Eli Lilly are the FDA approval process, patent expirations, pipeline concerns, the purchase of Imclone and how it will be integrated into the company, and finally the ongoing recession. Eli Lilly currently has drugs pending FDA approval, notably Effient, a blood-thinner. Effient’s approval has been delayed twice, and is currently going to be reviewed by a special committee within the FDA in 2009. Analysts believe that Effient can become the dominant drug used around the world grossing billions in revenue; however, the FDA has not approved it yet. Eli Lilly also has patents running out on several of its highest grossing drugs including Zyprexa, Cymbalta, and Gemzar between 2011 and 2013. These are Eli Lilly’s top three grossing drugs and the patent expiration will raise questions about their future pipeline after 2013, especially if Effient does not get approved. Overall with all these questions and risk factors we decided to go with our relative valuation, which shows us Eli Lilly is......

Words: 8055 - Pages: 33


...Eli Lilly & Company Descripción de la industria Industria farmacéutica, Salud. La industria farmacéutica partió de varias actividades distintas que estaban relacionadas con la obtención de sustancias utilizadas en la medicina. A comienzos del siglo 21, los botánicos, químicos o los propietarios de herbolarios obtenían partes secas de diversas plantas, recogidas localmente o en otros continentes. Los productos químicos y los minerales se adquirían con comerciantes de aceite y gomas. Boticarios y químicos profesionales elaboraban mayor cantidad de preparados de los que necesitaban para su propio uso y los vendían a granel a sus compañeros. Se encuentra la producción a granel de productos químicos (producción primaria) que se utiliza para la producción secundaria como pastillas, cápsulas, inyecciones, supositorios, etc. La mayoría de las compañías farmacéuticas se crearon antes de la II guerra mundial en diferentes países gracias al surgimiento económico y estabilidad política. Algunas de ellas son Allen & Hambury y Wellcome, de Londres, Merck, de Darmstadt (Alemania), y las empresas norteamericanas Parke Davis, Warner Lambert y Smithkline & French fueron fundadas por farmacéuticos. La utilización de nuevas técnica como la fabricación de moléculas más complicadas y el uso de aparatos cada vez más caros han aumentado en gran medida los precios de los fármacos. Lo anterior fue un problema debido a la presión de parte de los gobiernos por bajar los precios......

Words: 4514 - Pages: 19

Eli Lilly

...MANAGEMENT OF TECHNOLOGY Case Brief on Eli Lilly: The Evista Project TIMELINE 4000-2000 BC – Ancient Egyptians developed compresses around Skull to stop migraines. 1876 – Eli Lilly founded in Indianapolis, Indiana by Colonel Eli Lilly. 1970s – Early research in Lilly on Serotonin. 1988 – Prozac launched to market 1991 – Serotonin “1f” receptor cloned by Lilly’s collaborator, Synaptic Pharmaceutical Corporation. CNS group starts screening serotonin like compounds from Lilly’s historical library 1992 – Glaxo launched sumatriptin (Imitrex) 1994 March/April “Hot” lead compound found from the screen with good fit at the serotonin 1f receptor Kaldor gives combinatorial chemistry seminar to an in-house audience at Lilly March/June Improvement upon this lead made using traditional chemistry September Sphinx acquired December Schaus presents seminar on his research to other CNS research group leaders 1995 – PTAC(Project Approval Committee) meets to discuss strategic choices in migraine project 2001 – Projected launch, if approved, of Lilly’s migraine product 2003 - Patent protection of Prozac ends What is a heavyweight project team and how does it differ from a traditional approach used for organizing development projects at Eli Lilly? A functional structure is a traditional approach found in most mature and larger companies where people are grouped in disciplines that work under a sub-function manager. The different subfunctions coordinate ideas through detailed......

Words: 1655 - Pages: 7

Norton Lilly Case Review

...Norton Lilly International: Written Case ​Norton Lilly is an international shipping agency. They have 37 regional offices, which provided service to ships in 70 ports located in North America, Caribbean, Pacific, and the Middle East. Their services consist of booking freight for export, clearing inbound cargo with U.S. customs, fueling vessels, restocking vessels with supplies and provisions, and arranging cargo-handling services. The company started way back in 1841, 150 years ago to this case’s time period, starting with John Norton. In 1907, the company expanded to include the Lilly family. In 1925, the company expanded to become international, with the opening of a Norton Lilly office in Panama. In 2010, Norton Lilly is the market share leader. 1 ​Norton Lilly has been successful as a company for their entire 150 years of existence. This is an achievement by itself. Most companies are not continually successful for more than a decade, with economies, struggle to compete, technology advancements, and leadership/ownership. The one thing that stands out about Norton Lilly is the overpowering emphasis on having successful leadership in the company. When Norton Lilly slowed and had a $2.6 million net loss in 2006, they looked at what had been successful, and because of outside acquisitions of agencies, a lack of focus on bottom-line performance, and a poor focus on operational performance, they began a turnaround. Starting with good leaders, Norton Lilly used an......

Words: 881 - Pages: 4

Ellis Book

...Listening to Ellis story honestly broke my heart. I don’t come from a broken home but it truly breaks my heart when people have to deal with these situations on their own. It makes me feel happy that Ellis has faith and courage to leave that all behind and stand stronger than ever. While I was watching him sign those tragic events in class I couldn’t help but tear up. I don’t think I would ever be able to handle those events in my life. Losing loved ones is already a tough situation to deal with, but watching them die and not being able to call for help is just really sad. It’s a shame that throughout his childhood he didn’t have his parents for moral support and had to put up with his aunt on his own. I have difficulties of my own with my family but they don’t compare to what Ellis has experienced and it makes me feel like a brat because I have everything I could possibly need and I still find myself complaining and arguing with my parents. Sometimes we take the smallest of things for granted. Many of us have all these blessings while others are wishing for them. I am guilty of taking things for granted. Ellis stories made me feel very grateful for the life I live. What I learned from Ellis stories is that even though life may suck at the moment it is only temporary, things will turn around for the better. His life did turn around for the better; he moved away from all the craziness and is attending school. He just wants to help people who are having the struggles he......

Words: 322 - Pages: 2

Eli Lilly Case

...Eli Lilly is a leading pharmaceutical company located in Indianapolis, Indiana, which specializes in treatment of several high profile diseases. Evista, a newly developed drug by Eli Lilly, is an estrogen replacement therapy medicine for prevention of osteoporosis which through testing has seemed to lower the incidence of breast cancer in women. This FDA approved drug is expected to be a potential blockbuster and generate revenue of 1 billion US dollars per year for the company. Pharmaceuticals is a highly competitive market and it is imperative for the leading companies to recuperate their development costs and generate returns for stockholders as well as fund research and development for potential new drugs at almost a constant rate. With the profitable lifetime for drugs, in United States, being significantly shortened since the 1980’s, Lilly Research Laboratories was able to develop Evista in a much shorter time period by adopting a Matrix-Based development approach and utilizing heavyweight teams. This strayed from their usual path of function-based product development strategy. With the possibility of profound profits from the commercialization of Evista, Dr. Gus Watanabe has to weigh whether the increasing internal resistance to heavyweight teams and shortage of resources is worth it. Watanabe needs to make a decision about adopting this new successful heavyweight team approach for commercialization of Evista as well as product development. Changes in the past few......

Words: 2988 - Pages: 12


...that were available before Prozac, such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) for treating depression, were too toxic or tricky to use except by trained psychiatrists. In the early 1970s, Ray Fuller, a senior Lilly pharmacologist, had been following new European research showing that a low concentration of serotonin in the brain was linked to depression. A Lilly chemist Bryan Malloy had synthesized some compounds intended to boost serotonin without the side effects of the TCAs. Human research data produced consistent and positive data. The new lower dose human studies revealed that 20 mg once a day was better than placebo and just as effective as TCAs taken multiple times a day. Prozac also produced fewer side effects, and was not lethal in overdose. Dropout rates on Prozac were comparable to the other TCAs and lower than for placebo that contributed to its success. • Thoughtful Marketing Launch Plan: When Prozac was launched in January 1988, Ken Cohen, the Marketing Manager made sure that Lilly was fully educated about depression, serotonin, and the practice of psychiatry in general. This was necessary because Lilly didn’t know the psychiatry field and the field didn’t know Eli Lilly. Cohen also recognized that there would be significant reluctance within the company to enter this new market.Prozac threatened to alter the company’s view of itself. He proactively planned to educate and overcome initial resistance from within......

Words: 279 - Pages: 2

Eli Lilly Case Study

...Executive Summary With the evolution of the Pharmaceutical industry in the US and the current decline of the blockbuster products of Eli Lilly which were coming to an end of their life cycle, the company is in the process of developing three new products that plan to launch in 1996. A great number of factors such as decrease of the industry growth rate, steady decline of innovation, increasing competition from competitors, generic drug substitutes, government regulations and an ever increasing cost in manufacturing, R&D and quality protocols and processes have made the decision to launch new products into the market place a necessity and created a topic of debate within the management and leadership of the company. In response to these conditions, the management has established a company-wide initiative and goals to accomplish in the launching of their three new upcoming products. These goals were set up keeping in mind that the company wanted to bring new innovative products to their customers faster, cheaper and serving the needs of their customers. 1. Reduce manufacturing costs by 25%. 2. Reduce product development lead time by 50% as compared to the current lead time of 8 to 12 years. 3. Never Stock out – meet projected manufacturing demands. The dilemma facing this company and the upcoming challenge has given rise to a difficult decision by Steve Muller, Manager of Strategic Facilities and Planning at Eli Lily and Company. The decision was to decide on the......

Words: 1959 - Pages: 8

Case 6-3 Eli Lilly in India

...CASE 6-3 “Eli Lilly in India: Rethinking the Joint Venture Strategy” 1. I think Eli Lilly pursued the right strategy joining Ranbaxy Laboratories to enter the Indian market. While companies were using the global market to amortize the huge investments required to produce a new drug, they were hesitant to invest in countries where the intellectual property regime was weak. During the 1990s both companies had a strong reason for the joint venture. Ranbaxy wanted to make its presence globally and Lilly wanted to get their feet on Indian grounds. In 1992, Ranbaxy approached Lilly to investigate the possibility of supplying certain active ingredients or sourcing of intermediate products to Lilly in order to provide low cost sources of intermediate pharmaceutical ingredients. Based on the strategic alliance, Ranbaxy would supply certain products to the joint venture from its own portfolio that were currently being manufactured in India and then formulate and finish some of Lily’s products locally. From the beginning, both companies had a lot in common, they both believed in high ethical standards, technology and innovation, and future of patented products. They created the joint venture with $7.1 million capital and an initial subscribed equity capital of $3 million, with equal contribution from Lilly and Ranbaxy, leading to an equity ownership of 50 percent each. India, with an 800 million population had about 300 million of people that were considered to...

Words: 855 - Pages: 4

Lilly Ledbetter

...the Lilly Ledbetter case. Pay discrimination. Equal pay for equal work. Lilly’s employer short changed her pay, her overtime and her retirement, She was getting 40% less than male co- workers. 2. What laws were responsive (prior law) to the issues involved in the Lilly Ledbetter case? In 1963, John F. Kennedy signed into law pay equity, equal pay for equal work for women and minorities and previous law of Title VII in 1964. 3. How was the Lilly Ledbetter case resolved? Ledbetter lost her gender pay discrimination lawsuit gainst Goodyear after the Supreme Court ruled she did not file a complaint on time. The Supreme Court ruled, in a five-to-four decision against Ledbetter stating that she should have filed a complaint within six months of the company’s first decision to pay her less, and took away two years’ of her back pay. 4. What does the Lilly Ledbetter Act say about Fair Pay for the same work. It restored The Equal Pay Act (EPA) which prohibits sex-based wage discrimination between men and women in the same establishment who perform jobs that require substantially equal skill, effort, and responsibility under similar working conditions. 5. What is your reaction to this case, are you surprised that the mindset reflected in the CEO's comments to women professionals reflect old attitudes? It really upset me that women are still treated in this manner. Age old attitudes of women being inferior to men can still be found in many companies to date. Lilly is......

Words: 274 - Pages: 2

Case Analysis: Eli Lilly in India:

...1. Did Eli Lilly pursue the right strategy (i.e., should it have used a joint venture) to enter the Indian market? Why or why not? You should refer to Chapter 6 of the notes for guidance. With the upward trend of globalization, cross-border commercialization has become inherent in business strategies pursuing not only improved competitiveness but to avoid market share erosion. Expanding to new markets, reducing friction with socio-cultural and legal barriers, reduce capital costs, securing raw materials and implementing economies of scale are just a few motivations which to look abroad for and consider the intricacies of operating in another country. Changes in India’s economic policies from an import substitution to an export-driven one, was the legal foundation that allowed Eli Lilly to pursue its interest to market its drugs in India, where it already had relationships with local manufacturers to produce human or animal insulin for the Soviet Union market, but did not for the Indian market (Bartlett & Beamish, 2014, p. 524) The opportunity presented by Ranbaxy, the second largest pharmaceutical company in India, to supply certain active ingredients or intermediate products to formulate and complete Lilly’s, and for the Joint Venture (JV) to sell and distribute those products, was the perfect opportunity to enter a “new” market while sharing the costs and risks with a well-known and respected partner. With the then existing market conditions (Sales turnover caps,......

Words: 863 - Pages: 4

Eli Lilly Case

...------------------------------------------------- Report on ------------------------------------------------- Eli Lilly and Company- ------------------------------------------------- The Flexible Facility Decision ------------------------------------------------- ------------------------------------------------- Course Title ------------------------------------------------- Managerial Written Communication ------------------------------------------------- ------------------------------------------------- Submitted to ------------------------------------------------- Prof. Mukul Vasavada ------------------------------------------------- & ------------------------------------------------- Prof. Nayana Shah ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- Submitted By ------------------------------------------------- Ankush Huddar (04) ------------------------------------------------- ------------------------------------------------- On ------------------------------------------------- 8th December, 2011 ------------------------------------------------- Adani Institute of Infrastructure Management ------------------------------------------------- PGPIM Batch III 2011-2012 ------------------------------------------------- Eli Lilly and Company To: | Chairman,Manufacturing Strategy Committee | From: | Steve......

Words: 1810 - Pages: 8

Eli Lilly Case Study

...University of Maryland Case Study Analysis Eli Lilly: Developing Cymbalta Case Study AMBA 650 Section 1131 Kelvin Harris January 24, 2012 Executive Summary Eli Lilly and Company resounding success was the arrival of Prozac in 1988. By mid-1988, a new anti-depressant team was formed to find and develop a drug that would be the successor to Prozac. The strategic issues and problems they faced were developing a new drug to replace Prozac, meeting the company budget constraints to perform clinical trials, and finally launch the new drug by mid-2001. The analysis and evaluation revealed that the pharmaceutical industry is changing fast and it usually takes a long time and millions of dollars to develop a new drug. The recommendation for Eli Lilly is to take the lead in developing the new drug Cymbalta, invest a stable share of the company revenue, seek the FDA approval for the development of Cymbalta before going to market, and not change their market plan from the FDA approved Cymbalta dosage of 20 mg twice daily. Introduction Eli Lilly and Company was founded by Colonel Eli Lilly, Lilly’s namesake, in 1876 when he purchased a laboratory on Pearl Street in Indianapolis, Indiana. Eli Lilly was a pharmacist who had served in the Union Army during the Civil War. The company success included creating the process for applying gelatin-coating to pills for easier swallowing and the introduction of Iletin which was the first mass-produced insulin. ......

Words: 1938 - Pages: 8

Eli Lilly Case

...Running head: ELI LILLY – DEVELOPING CYMBALTA CASE ANALYSIS 1 Week 4: Eli Libby – Developing Cymbalta Case Analysis Mary Juanita Hawkins University of Maryland University College Author Note This individual assignment was prepared for AMBA650, Section 9245, taught by Professor Philemon O. Oyewole. Introduction Eli Lilly and Company was established on May 10, 1876 in Indianapolis, IN and has been in business more than 132 years. The founder of this pharmaceutical company was Colonel Eli Lilly who was a union army member during the Civil War. This company deals with the development, discovery, sell, and manufacturer of drugs, such as Prozac and integrates supply-chain management within its departments. The first success that the company achieved was the coating of pills using gelatin. In 1923, the company marked another success by introducing Iletin that was used in improving diabetes. This project was the first largest insulin production that the company together with the University of Toronto invented. All through the 1950’s, various advancements were introduced such as the invention of the oral penicillin and the antibiotic known as Erythromycin. Prozac was produced in 1988 and latter succeeded in 1990. In 2000, the drug Zyprexa was utilized in the treatment of schizophrenia and later, the drug Gemzer was introduced for chemotherapy. Before Prozac the treatment available was Tofranil also......

Words: 2475 - Pages: 10

Elli Lilly in India

...The Problem Joint Ventures do not always work and when they do they don’t work indefinitely. What Eli Lilly and Ranbaxy are facing now is the dilemma of rather to continue with their JV, Eli Lilly Ranbaxy, or should they separate and continue each one by its own means. The situation represents both a problem and an opportunity to both companies, as there are important trade-offs to be considered before any decision is taken. The Environment In the last decade the environment for the pharmaceutical industry changed radically in India. Before the 1990’s there were no regulations for patent recognition and the government had an active role in establishing drug prices through the DPCO, which were situated amongst the lowest in the world. Profit margins were also regulated at around 6% of sales. As a result many of the multinationals started exiting the Indian market. As India enter the GATT and the WTO in 1994 patent protection would become active in India from 2004-2005. In the international arena, patent regulation was also little by little becoming stronger and many of the big players were going through M&A processes that further increased the sales concentration in few companies. These companies had a hard time competing with local laboratories that produced generic drugs with no R&D expenses and at a fraction of the price. Eli Lilly Ranbaxy portraits the example of the traditional JV in which Ranbaxy, a company from less-industrialized country, offered the knowledge......

Words: 1256 - Pages: 6